A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection

Inclusion Criteria: * Male or female patients 18 years or older with body weight \>40kg * Written informed consent * Presented within 48 hours of onset of influenza-like illness * Presumptive diagnosis of H1N1 satisfying the following clinical and laboratory criteria: * Clinical criteria * Fever \>38 oC (Infrared Forehead Thermometer will be used to measure the Temporal Artery Temperature under the skin) AND * At least one upper respiratory tract infection (cough, running nose, sore throat) * Laboratory criteria Positive rapid test result for influenza A (by Influenza Rapid Diagnostic test) within 48 hours of onset of flu-like symptoms Exclusion Criteria: * Age below 18 years * Persons who lack the ability to care for themselves * Patient with critical condition or already developed severe respiratory distress with hypoxaemia on presentation * Pregnancy or lactation * Coexisting liver disease * Coexisting cardiovascular disease except stable hypertension without complication * Coexisting chronic pulmonary disease * Coexisting immuno-compromised medical conditions or on concurrent immunosuppressive therapies * Renal failure * Terminal malignancies or terminal end-organ failure with an estimated life-expectancy of less than 3 months * Known intolerance to oseltamivir or zanamivir * Known history of significant neurological disorders that can compromise respiratory function or the handling of respiratory secretions or that can increase the risk for aspiration or those * Subjects who have received oseltamivir as prophylaxis for H1N1 infection * Subjects who have received any investigational drug within 1 month prior to study entry * Subjects with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study